Drugs / Neoantigen Peptides
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT05475106 | May 2022 → Nov 2025 | neoplasm | Instituto de Medicina Regenerativa | Unknown | No outcome recorded |
| Phase 0 | NCT04509167 | Aug 2020 → Jun 2022 | neoplasm | Instituto de Medicina Regenerativa | Completed | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT04072900 | Apr 2020 → Sep 2021 | cutaneous melanoma | Xiangya Hospital of Central South University | Unknown | No outcome recorded |
| Phase 1 | NCT02950766 | Mar 2019 → Dec 2027 expected | kidney cancer | Patrick Ott, MD, PhD | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Neoantigen Peptides | “NeoAntigen peptides:4 x 2 mg the total peptides given on days 84，87，91，98，105，133，and 161” NCT04072900 ↗3“Neovax is a combination of Poly-ICLC and Neoantigen Peptides” NCT02950766 ↗ |
| Modality | Vaccine | “Personalized Neoantigen Cancer Vaccine” NCT02950766 ↗ |